These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29852079)

  • 1. Transcriptomal signatures of vaccine adjuvants and accessory immunostimulation of sentinel cells by toll-like receptor 2/6 agonists.
    Salyer ACD; David SA
    Hum Vaccin Immunother; 2018 Jul; 14(7):1686-1696. PubMed ID: 29852079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
    Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
    Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of murine embryonic fibroblasts to define Toll-like receptor activation and specificity.
    Kurt-Jones EA; Sandor F; Ortiz Y; Bowen GN; Counter SL; Wang TC; Finberg RW
    J Endotoxin Res; 2004; 10(6):419-24. PubMed ID: 15588425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity.
    Seya T; Shime H; Takeda Y; Tatematsu M; Takashima K; Matsumoto M
    Cancer Sci; 2015 Dec; 106(12):1659-68. PubMed ID: 26395101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced immunostimulatory activity of in silico discovered agonists of Toll-like receptor 2 (TLR2).
    Murgueitio MS; Ebner S; Hörtnagl P; Rakers C; Bruckner R; Henneke P; Wolber G; Santos-Sierra S
    Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt A):2680-2689. PubMed ID: 28734965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.
    Hornung V; Rothenfusser S; Britsch S; Krug A; Jahrsdörfer B; Giese T; Endres S; Hartmann G
    J Immunol; 2002 May; 168(9):4531-7. PubMed ID: 11970999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic Exposure of Gingival Fibroblasts to TLR2 or TLR4 Agonist Inhibits Osteoclastogenesis but Does Not Affect Osteogenesis.
    Karlis GD; Schöningh E; Jansen IDC; Schoenmaker T; Hogervorst JMA; van Veen HA; Moonen CGJ; Łagosz-Ćwik KB; Forouzanfar T; de Vries TJ
    Front Immunol; 2020; 11():1693. PubMed ID: 32793243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids.
    Proost P; Verpoest S; Van de Borne K; Schutyser E; Struyf S; Put W; Ronsse I; Grillet B; Opdenakker G; Van Damme J
    J Leukoc Biol; 2004 May; 75(5):777-84. PubMed ID: 14996826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10.
    Mauldin IS; Wang E; Deacon DH; Olson WC; Bao Y; Slingluff CL
    Int J Cancer; 2015 Sep; 137(6):1386-96. PubMed ID: 25765738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and Epigenetic Regulation of the Innate Immune Response to Gout.
    de Lima JD; de Paula AGP; Yuasa BS; de Souza Smanioto CC; da Cruz Silva MC; Dos Santos PI; Prado KB; Winter Boldt AB; Braga TT
    Immunol Invest; 2023 Apr; 52(3):364-397. PubMed ID: 36745138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors.
    Nishiya T; DeFranco AL
    J Biol Chem; 2004 Apr; 279(18):19008-17. PubMed ID: 14976215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergism of toll-like receptor 2 (TLR2), TLR4, and TLR6 ligation on the production of tumor necrosis factor (TNF)-alpha in a spontaneous arthritis animal model of interleukin (IL)-1 receptor antagonist-deficient mice.
    Jung YO; Cho ML; Lee SY; Oh HJ; Park JS; Park MK; Park MJ; Ju JH; Kim SI; Park SH; Kim HY; Min JK
    Immunol Lett; 2009 Apr; 123(2):138-43. PubMed ID: 19428561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Response of Gestational Tissues to TLR3 Viral Priming Prior to Exposure to Bacterial TLR2 and TLR2/6 Agonists.
    Rasheed ZBM; Lee YS; Kim SH; Rai RK; Ruano CSM; Anucha E; Sullivan MHF; MacIntyre DA; Bennett PR; Sykes L
    Front Immunol; 2020; 11():1899. PubMed ID: 32983111
    [No Abstract]   [Full Text] [Related]  

  • 14. TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors.
    Agrawal S; Gupta S
    J Clin Immunol; 2011 Feb; 31(1):89-98. PubMed ID: 20821041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonists of toll-like receptors 2 and 4 activate airway smooth muscle via mononuclear leukocytes.
    Morris GE; Whyte MK; Martin GF; Jose PJ; Dower SK; Sabroe I
    Am J Respir Crit Care Med; 2005 Apr; 171(8):814-22. PubMed ID: 15657467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-like receptors differentially regulate CC and CXC chemokines in skeletal muscle via NF-kappaB and calcineurin.
    Boyd JH; Divangahi M; Yahiaoui L; Gvozdic D; Qureshi S; Petrof BJ
    Infect Immun; 2006 Dec; 74(12):6829-38. PubMed ID: 16982839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFNs activate toll-like receptor gene expression in viral infections.
    Miettinen M; Sareneva T; Julkunen I; Matikainen S
    Genes Immun; 2001 Oct; 2(6):349-55. PubMed ID: 11607792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand.
    Nagase H; Okugawa S; Ota Y; Yamaguchi M; Tomizawa H; Matsushima K; Ohta K; Yamamoto K; Hirai K
    J Immunol; 2003 Oct; 171(8):3977-82. PubMed ID: 14530316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells.
    Re F; Strominger JL
    J Immunol; 2004 Dec; 173(12):7548-55. PubMed ID: 15585882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants.
    Kumar S; Sunagar R; Gosselin E
    Front Immunol; 2019; 10():1144. PubMed ID: 31191528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.